Associations of epicardial fat thickness and circulating markers of myocardial fibrosis in patients with myocardial infarction

Aim: to determine the association of the thickness of epicardial adipose tissue (EAT) with the level of biological markers and the degree of myocardial fibrosis one year after myocardial infarction (MI) in patients with visceral obesity (VO).

Materials and methods: the study included 88 patients with MI who were then divided into 2 groups: with and without it. VO and myocardial fibrosis a year after MI were measured by magnetic resistance tomography (MRI). Serum levels of COL 1, PICP, PIIINP on the 1st day of MI and after 1 year were determined by enzyme-linked immunosorbent assay (ELISA). The results were analyzed using Statistica 6.1 and SPSS 17.0 for Windows.

Results: in the presence of VO, an increase in the thickness of EАT, development of cardiofibrosis after 1 year, and an increase in circulating markers of fibrosis in the acute period of MI were observed. A direct correlation was found between the thickness of EАT and the concentration of markers of myocardial fibrosis both on the 1st day of MI and after a year, as well as the percentage of cardiofibrosis and COL1, PICP, PIIINP, on the 1st day of MI for both groups, one year after MI this relationship persisted only in individuals with VO (r = 0.54, p = 0.01; r = 0.33, p = 0.00; r = 0.51, p = 0.01).

Conclusions: the fact of VO in patients with MI is associated both with an increase in the thickness of ECT, the development of cardiofibrosis one year after MI, and with an increase in serum levels of COL 1, PICP and PIIINP on the 1st day and a year after the MI. In addition, the thickness of EАT is directly proportional to the degree of VO, and the levels of myocardial fibrosis markers depend on the value of EАT, this makes it possible to consider EАT as an additional indicator of myocardial fibrosis

1. Platonov P.G., Mitrofanova L.B., Orshanskaya V., Ho S.Y. Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age. J. Am. Coll. 2011; 58 (21): 2225–2232.

2. Aoki T., Fukumoto Y., Sugimura K., Oikawa M., Satoh K., Nakano M., Nakayama M., Shimokawa H. Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. Comparison between preserved and reduced ejection fraction heart failure. Circulat. J. 2011; 75: 2605–2613.

3. Azevedo C.F., Nigri M., Higuchi M.L., Pomerantzeff P.M., Spina G. S., Sampaio R. O., Tarasoutchi F., Grinberg M., Rochitte C.E. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J. Am. Coll. 2010; 56: 278–287.

4. Wu Y., Zhang A., Hamilton D.J., Deng T. Epicardial fat in the maintenance of cardiovascular health. Methodist DeBakey Cardiovascular J. 2017; 13 (1): 20–24.

5. Fuster J.J., Ouchi N., Gokce N., Walsh K. ObesityInduced changes in adipose tissue microenvironment and their impact on cardiovascular disease. Circulation. Res. 2016; 118 (11): 1786–1807.

6. Fox C.S., Massaro J.M., Hoffmann U., Pou K. M., Maurovich-Horvat P., Liu C.Y., Vasan R. S., Murabito J.M., Meigs J.B., Cupples L.A., D’Agostino R.B., O’Donnell C.J. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007; 116: 39–48.

7. Venteclef N., Guglielmi V., Balse E., Gaborit B., Cotillard A., Atassi F., Amour J., Leprince P., Dutour A., Clément K., Hatem S.N. Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines. Eur. Heart J. 2015; 36: 795–805.

8. Каретникова В.Н., Кашталап В.В., Косарева С.Н., Барбараш О.Л. Фиброз миокарда: современные аспекты проблемы. Терапевт. арх. 2017; 89 (1): 88–93.

9. Ma Y., Iyer R.P., Jung M., Czubryt M.P., Lindsey M. Cardiac Fibroblast Activation Post-Myocardial Infarction: Current Knowledge Gaps. Trends in Pharmacol. Sci. 2017; 38 (5): 448–458.

10. López B., González A., Ravassa S., Beaumont J., Moreno M.U., José G.S., Querejeta R., Díez J. Circulating biomarkers of myocardial fibrosis. J. Am. Coll. 2015; 65 (22): 2449–2456.

11. An Z., Yang G., Zheng H., Nie W., Liu G. Biomarkers in patients with myocardial fibrosis. Open Life Sci. 2017; 12: 337–344.

12. Ellims A.H., Taylor A.J., Mariani J.A., Ling L., Iles L.M., Maeder M.T., Kaye D.M. Evaluating the utility of circulating biomarkers of collagen synthesis in hypertrophic cardiomyopathy. Сirculation: Eur. J. Heart Failure. 2014; 7: 271–278.

13. Wong T.C., Piehler K., Meier C.G., Testa S.M., Klock A.M., Aneizi A.A., Shakesprere J., Kellman P., Shroff S.G., Schwartzman D.S., Mulukutla S.R., Simon M.A., Schelbert E.B. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012; 126: 1206–1216.

14. Gruzdeva O., Evgenya U., Dyleva Y., Borodkina D., Akbasheva O., Belik E., Karetnikova V., Brel N., Kokov A., Kashtalap V., Barbarash O. Relationships between epicardial adipose tissue thickness and adipofibrokine indicator profiles post-myocardial infarction. Cardiovasc. Diabetol. 2018; 17: 40.

15. Rockey D.C., Bell P.D., Hill J.A. Fibrosis – a common pathway to organ injury and failure. New Engl. J. Med. 2015; 372: 1138–1149.

16. Chang L., Milton H., Eitzman D.T., Chen Y.E. Paradoxical roles of perivascular adipose tissue in atherosclerosis and hypertension. Circ. J. 2013; 77 (1): 11–8.

17. Веселовская Н.Г., Чумакова Г.А., Елыкомов В.А., Гриценко О.В., Дашкова А.А., Трубина Е.В., Киселева Е.В. Факторы риска рестеноза после коронарного стентирования у пациентов с ожирением. Кардиоваскулярная терапия и профилактика. 2013; 12 (30): 4–9.

18. Jong S., Veen T., Bakker J., Vos M., Rijen H. Biomarkers of myocardial fibrosis. J. Cardiovasc. Pharmacol. 2011; 57: 522–535.

19. Löfsjögård J., Kahan T., Díez J., López B., González A, Edner M., Henriksson P, Mejhert M., Persson H. Biomarkers of collagen type I metabolism are related to B-type natriuretic peptide, left ventricular size, and diastolic function in heart failure. Cardiovascular. Med. 2014; 6: 463–469.

20. Zannad F., Alla F., Dousset B., Perez A., Pit B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation. 2000; 102: 2700–2706.

21. Драпкина О.М., Черкунова Е.В. Оценка нарушений сократительной функции предсердий и фиброза как предикторов развития хронической сердечной недостаточности. Рациональная фармакотерапия в кардиологии. 2014; 10 (2): 231–237.

22. Cicoira M., Rossi A., Bonapace S., Zanolla L., Golia G., Franceschini L., Caruso B., Marino P.N., Zardini P. Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure. J. Card. Fail. 2004; 10: 403–411.

23. Swartz M.F., Fink G.W., Sarwar M.F., Hicks G.L., Yu Y., Hu R., Lutz C.J., Taffet S.M., Jalife J. Elevated Pre-Operative Serum Peptides for Collagen I and III Synthesis Result in Post-Surgical Atrial Fibrillation. J. Am. Coll. 2012; 60 (18): 1799–1806.

24. Plaksej R., Kosmala W., Frantz S., Herrmann S., Niemann M., Störk S., Wachter R., Angermann C., Ertl G., Bijnens B., Weidemann F. Relation of circulating markers of fibrosis and progression of left and right ventricular dysfunction in gypertensive patients with heart failure. J. Hypertens. 2009; 27 (12): 2483–2491.

25. Quilliot D., Alla F., Bohme P., Bruntz J-F., Hammadi M., Dousset B., Ziegler O., Zannad F. Myocardial collagen turnover in normotensive obese patients: relation to insulin resistance. Int. J. Obes. Relat. Metab. Disord. 2005; 29: 1321–1328.

26. Jiménez-Navarro M.F., Gómez-Doblas J.J., CabreraBueno F., Cruz-Ocaña E., Rodríguez-Bailón I., RuizGaldón M., Morell M., Molero E., Teresa-Galván E. Collagen Synthesis and Heart Failure. Revista Española de Cardiología. 2005; 58 (8): 975–978.

27. Lоpez B., Querejeta R., González A., Sánchez E., Larman M., Díez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J. Am. Coll. 2004; 43: 2028–2035.

28. Querejeta R., Varo N., López B., Larman M., Artinano E., Etayo J.C., Ubago J.L.M., Gutierrez-Stampa M., Emparanza J.I., Gil M.J., Monreal I., Mindan J.P., Diez J. Serum carboxy-terminal pro-peptide procollagen type I is a marker of myocardial fibrosis in hypertensive heart disease. Circulation. 2000; 101: 1729–1735.

29. Lоpez B., Gonzalez A., Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation. 2010; 121: 1645–1654.

30. Gruzdeva O., Uchasova E., Dyleva Y., Karetnikova V., Brel N., Kokov A., Barbarash O., Borodkina D., Akbasheva O. Relationship between epicardial and perivascular fatty tissue and adipokinecytokine level in coronary artery disease patients. PLoS One. 2019; 14(6): e0208156.

31. Печерина Т.Б., Груздева О.В., Барбараш О.Л. Роль матриксных металлопротеиназ в формировании патологического ремоделирования миокарда левого желудочка у больных инфарктом миокарда с подъемом сегмента ST. Фундамент. и клин. медицина. 2019; 4(2): 28–41.